CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations at the Society for Neuroscience (SFN) 2016 Annual Meeting, taking place November 12-16, 2016 in San Diego, CA.
Below is the schedule for the presentations:
Date: Saturday, November 12, 2016
Poster Presentation
Time: 1:00 p.m. – 5:00 p.m. PT
Location: Halls B-H, San
Diego Convention Center
Poster Number: 34.04 / E6
Title: Pharmacology
of the human ε subunit from the GABAA receptors
Date: Monday, November 14, 2016
Poster Presentation Time: 1:00
p.m. – 4:00 p.m. PT
Location: Halls B-H, San Diego
Convention Center
Poster Number: 407.11 / K17
Title: Neuroactive
steroids exhibit synergistic interactions with barbiturates at the GABAA
receptor in vitro and this impacts on activity in an animal model
of seizure
Date: Tuesday, November 15, 2016
Poster Presentation Time: 8:00
a.m. – 12:00 p.m. PT
Location: Halls B-H, San Diego
Convention Center
Poster Number: 497.10 / F21
Title: Positive
allosteric modulation of NMDA receptors ameliorate behavioral and
electrophysiological phenotypes in a pre-clinical model of
Smith-Lemli-Opitz Syndrome
Date: Wednesday, November 16, 2016
Poster Presentation
Time: 8:00 a.m. – 12:00 p.m. PT
Location: Halls
B-H, San Diego Convention Center
Poster Number: 690.11 / L8
Title: Phenytoin
halts convulsions, but not electrographic seizure activity, in a rat
model of status epilepticus, whereas both are eliminated by next
generation neuroactive steroids
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and is being developed for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.